The United Arab Emirates has become the second country in the world, after the United States, to approve the use of Lipfendra for treating elevated levels of low-density lipoprotein (LDL), or 'bad' cholesterol, reports infohub.kz.
The approval was granted by the Emirates Drug Establishment (EDE). The drug is intended for adults with high LDL cholesterol, including certain hereditary forms of the condition.
Lipfendra is available as a tablet taken once daily. It is prescribed by a physician as part of a comprehensive treatment plan alongside a balanced diet and regular physical activity.
What sets Lipfendra apart is that it is the world's first oral PCSK9 inhibitor. Unlike statins, which reduce cholesterol production in the liver, it works through a different mechanism. The drug blocks the PCSK9 protein, enabling liver cells to more effectively remove LDL from the bloodstream. Previously, this class of medication was only available as injections.
According to clinical trials, in patients already on maximally tolerated statin therapy, Lipfendra further reduced 'bad' cholesterol levels by approximately 56–59%.
The EDE noted that the registration of the new drug expands treatment options for patients who require more intensive cholesterol lowering alongside a healthy lifestyle.
High LDL cholesterol is considered a major risk factor for cardiovascular diseases, including heart attack and stroke. If lifestyle changes and standard therapy are insufficient to achieve target cholesterol levels, patients may need additional medications.